Interest of fecal calprotectine dosage in inflammatory bowel diseases, state of the art and perspectives.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Annales de Biologie Clinique

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1684/abc.2016.1172PMID 27492691
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serial fecal calprotectin measurements to detect endoscopic recurrence in postoperative Crohn's disease: is colonoscopic surveillance no longer needed?

  2015cited by this paper
• Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.

  2015cited by this paper
• Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.

  2015cited by this paper
• The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

  2014cited by this paper
• The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease

  2014cited by this paper
• The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis.

  2014cited by this paper
• Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders

  2014cited by this paper
• Clinical Utility And Diagnostic Accuracy of Faecal Calprotectin For IBD At First Presentation To Gastroenterology Services In Adults Aged 16–50 Years

  2014cited by this paper
• Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease

  2014cited by this paper
• Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?

  2014cited by this paper
• Optimising monitoring in the management of Crohn's disease: a physician's perspective.

  2013cited by this paper
• Screening for type 2 diabetes: a short report for the National Screening Committee.

  2013cited by this paper
• Fecal Calprotectin in Pediatric Inflammatory Bowel Disease: A Systematic Review

  2013cited by this paper
• Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes

  2013cited by this paper
• Fecal Calprotectin Levels Predict the Clinical Course in Patients With New Onset of Ulcerative Colitis

  2013cited by this paper
• Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study

  2013cited by this paper
• Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

  2012cited by this paper
• Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta‐analysis of prospective studies

  2012cited by this paper
• Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.

  2012cited by this paper
• Evaluation of Prevent ID and Quantum Blue rapid tests for fecal calprotectin

  2012cited by this paper
• Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels.

  2011cited by this paper
• The changing pattern of Crohn’s disease incidence in northern France: a continuing increase in the 10‐ to 19‐year‐old age bracket (1988–2007)

  2011cited by this paper
• Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?

  2010cited by this paper
• The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.

  2010cited by this paper
• Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males.

  2010cited by this paper
• Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis

  2010cited by this paper
• Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI

  2010cited by this paper
• Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease

  2009cited by this paper
• Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse

  2009cited by this paper
• Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases

  2008cited by this paper
• Can Calprotectin Predict Relapse Risk in Inflammatory Bowel Disease?

  2008cited by this paper
• Inflammatory bowel disease: clinical aspects and established and evolving therapies

  2007cited by this paper
• Prospective evaluation of faecal neutrophil‐derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin

  2007cited by this paper
• Inflammatory bowel diseases: the paediatric gastroenterologist's perspective

  2007cited by this paper
• The Epidemiology of Inflammatory Bowel Disease in Canada: A Population-Based Study

  2006cited by this paper
• Diagnostic Precision of Anti-Saccharomyces cerevisiae Antibodies and Perinuclear Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease

  2006cited by this paper
• American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.

  2006cited by this paper
• Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease

  2005cited by this paper
• Infliximab for induction and maintenance therapy for ulcerative colitis.

  2005cited by this paper
• [Digestive tract immunology and Crohn disease].

  2004cited by this paper
• Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children.

  2003cited by this paper
• Faecal calprotectin: a marker of inflammation throughout the intestinal tract

  2002cited by this paper
• Improved assay for fecal calprotectin.

  2000cited by this paper
• Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.

  2000cited by this paper
• Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease.

  1999cited by this paper
• Cyclosporine in severe ulcerative colitis refractory to steroid therapy.

  1994cited by this paper
• Predictability of the postoperative course of Crohn's disease.

  1990cited by this paper
• A simple index of Crohn's-disease activity.

  1980cited by this paper

• Systematic review on fecal calprotectin in cystic fibrosis

  2022cites this paper
• Divalent cations influence the dimerization mode of murine S100A9 protein by modulating its disulfide bond pattern.

  2020cites this paper